CONMED Corp — Director's Dealing 2021

Mar 4, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CONMED CORP (CNMD)
CIK: 0000816956
Period of Report: 2021-03-01

Reporting Person: Pelletier Johonna Marie (Treasurer and VP, Tax)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-01	Common Stock	M	1900	$39.87	Acquired	5781	Direct
2021-03-01	Common Stock	S	1900	$123.0305	Disposed	3881	Direct
2021-03-01	Common Stock	M	2000	$41.93	Acquired	5881	Direct
2021-03-01	Common Stock	S	2000	$122.5528	Disposed	3881	Direct
2021-03-01	Common Stock	M	6100	$59.96	Acquired	9981	Direct
2021-03-01	Common Stock	S	6100	$122.3424	Disposed	3881	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-01	Options To Purchase Common Stock	$39.87	M	1900	Disposed	2026-03-01	Common Stock (1900)	Direct
2021-03-01	Options To Purchase Common Stock	$41.93	M	2000	Disposed	2027-03-01	Common Stock (2000)	Direct
2021-03-01	Options To Purchase Common Stock	$59.96	M	6100	Disposed	2028-03-01	Common Stock (6100)	Direct
2021-03-01	Options To Purchase Common Stock	$122.55	A	12000	Acquired	2031-03-01	Common Stock (12000)	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122.95 to $123.09. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122.50 to $122.68. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122.05 to $122.57. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.

F4: The stock options were granted under the Company's 2015 Amended and Restated Long-Term Incentive Plan and generally vest in equal amounts over a five year period.

F5: The stock options were granted under the Company's 2018 Long-Term Incentive Plan and generally vest in equal amounts over a five year period